← Back to patent-cliff list
CG-0255 (PO)
Tier C — Watch / tradeCG-0255 (PO)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：P2RY12
Indications (approved)：Cardiac and vascular disorders, Coronary artery disease, Peripheral arterial disease, Myocardial infarction, Stroke, Ischaemic stroke, 动脉血栓形成, Atherosclerosis
Regional status
US
Phase I
2026-06-01
EU
-
China
Phase I
2025-01-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CG-0255 (PO)?
Approved indications include: Cardiac and vascular disorders, Coronary artery disease, Peripheral arterial disease, Myocardial infarction, Stroke, Ischaemic stroke, 动脉血栓形成, Atherosclerosis.
When does the CG-0255 (PO) patent expire?
No public expiry year is available for CG-0255 (PO) yet; this page updates once verified.
How do I get a quote for CG-0255 (PO) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01